These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

130 related items for PubMed ID: 9785608

  • 1. Effect of lodoxamide on tear leukotriene levels in giant papillary conjunctivitis associated with ocular prosthesis.
    Akman A, Irkeç M, Orhan M, Erdener U.
    Ocul Immunol Inflamm; 1998 Sep; 6(3):179-84. PubMed ID: 9785608
    [Abstract] [Full Text] [Related]

  • 2. Effects of lodoxamide, disodium cromoglycate and fluorometholone on tear leukotriene levels in vernal keratoconjunctivitis.
    Akman A, Irkeç M, Orhan M.
    Eye (Lond); 1998 Sep; 12 ( Pt 2)():291-5. PubMed ID: 9683957
    [Abstract] [Full Text] [Related]

  • 3. Role of tear inflammatory mediators in contact lens-associated giant papillary conjunctivitis in soft contact lens wearers.
    Irkeç MT, Orhan M, Erdener U.
    Ocul Immunol Inflamm; 1999 Mar; 7(1):35-8. PubMed ID: 10410873
    [Abstract] [Full Text] [Related]

  • 4. Tear LTC4 levels in patients with subclinical contact lens related giant papillary conjunctivitis.
    Sengör T, Irkeç M, Gülen Y, Taşeli M, Erker H.
    CLAO J; 1995 Jul; 21(3):159-62. PubMed ID: 7586473
    [Abstract] [Full Text] [Related]

  • 5. Efficacy of lodoxamide eye drops on tear fluid cytology of patients with vernal conjunctivitis.
    Oguz H, Bitiren M, Aslan OS, Ozardali I.
    Acta Med Okayama; 1999 Jun; 53(3):123-6. PubMed ID: 10410789
    [Abstract] [Full Text] [Related]

  • 6. Tear eotaxin levels in giant papillary conjunctivitis associated with ocular prosthesis.
    Sarac O, Erdener U, Irkec M, Us D, Gungen Y.
    Ocul Immunol Inflamm; 2003 Sep; 11(3):223-30. PubMed ID: 14566648
    [Abstract] [Full Text] [Related]

  • 7. Tear lactoferrin levels in patients with external inflammatory ocular disease.
    Ballow M, Donshik PC, Rapacz P, Samartino L.
    Invest Ophthalmol Vis Sci; 1987 Mar; 28(3):543-5. PubMed ID: 3030955
    [Abstract] [Full Text] [Related]

  • 8. Tear histamine and histaminase during the early (EPR) and late (LPR) phases of the allergic reaction and the effects of lodoxamide.
    Leonardi AA, Smith LM, Fregona IA, Salmaso M, Secchi AG.
    Eur J Ophthalmol; 1996 Mar; 6(2):106-12. PubMed ID: 8823580
    [Abstract] [Full Text] [Related]

  • 9. Efficacy of lodoxamide eye drops on mast cells and eosinophils after allergen challenge in allergic conjunctivitis.
    Bonini S, Schiavone M, Bonini S, Magrini L, Lischetti P, Lambiase A, Bucci MG.
    Ophthalmology; 1997 May; 104(5):849-53. PubMed ID: 9160033
    [Abstract] [Full Text] [Related]

  • 10. Mechanisms and comparison of anti-allergic efficacy of topical lodoxamide and cromolyn sodium treatment in vernal keratoconjunctivitis.
    Avunduk AM, Avunduk MC, Kapicioglu Z, Akyol N, Tavli L.
    Ophthalmology; 2000 Jul; 107(7):1333-7. PubMed ID: 10890862
    [Abstract] [Full Text] [Related]

  • 11. Effect of lodoxamide and disodium cromoglycate on tear eosinophil cationic protein in vernal keratoconjunctivitis.
    Leonardi A, Borghesan F, Avarello A, Plebani M, Secchi AG.
    Br J Ophthalmol; 1997 Jan; 81(1):23-6. PubMed ID: 9135403
    [Abstract] [Full Text] [Related]

  • 12. Tear and serum eosinophil cationic protein levels in seasonal allergic conjunctivitis.
    Acar N, Toker E, Kazokoğlu H.
    Eur J Ophthalmol; 2003 Oct; 13(8):671-5. PubMed ID: 14620169
    [Abstract] [Full Text] [Related]

  • 13. Treatment of common ocular allergic disorders; a comparison of lodoxamide and NAAGA.
    Denis D, Bloch-Michel E, Verin P, Sebastiani A, Tazartes M, Helleboid L, Di Giovanni A, Lecorvec M.
    Br J Ophthalmol; 1998 Oct; 82(10):1135-8. PubMed ID: 9924299
    [Abstract] [Full Text] [Related]

  • 14. Comparison of lodoxamide 0.1% ophthalmic solution and levocabastine 0.05% ophthalmic suspension in vernal keratoconjunctivitis.
    Verin P, Allewaert R, Joyaux JC, Piozzi E, Koliopoulos J, Bloch-Michel E, Lodoxamide Study Group.
    Eur J Ophthalmol; 2001 Oct; 11(2):120-5. PubMed ID: 11456011
    [Abstract] [Full Text] [Related]

  • 15. Safety and efficacy of lodoxamide in vernal keratoconjunctivitis.
    Das D, Khan M, Gul A, Alam R.
    J Pak Med Assoc; 2011 Mar; 61(3):239-41. PubMed ID: 21465936
    [Abstract] [Full Text] [Related]

  • 16. Tear lysozyme and lactoferrin levels in giant papillary conjunctivitis and vernal conjunctivitis.
    Rapacz P, Tedesco J, Donshik PC, Ballow M.
    CLAO J; 1988 Mar; 14(4):207-9. PubMed ID: 3147820
    [Abstract] [Full Text] [Related]

  • 17. Levels of prostaglandin E2 and leukotriene B4 in tears of vernal conjunctivitis patients during a therapeutic trial with indomethacin.
    Nathan H, Naveh N, Meyer E.
    Doc Ophthalmol; 1994 Mar; 85(3):247-57. PubMed ID: 7924852
    [Abstract] [Full Text] [Related]

  • 18. [Evaluation of the efficacy and safety of lodoxamide in patients with allergic eye diseases].
    Dekaris I, Gabrić N, Lazić R, Bosnar D, Cima I, Stipić A.
    Acta Med Croatica; 2002 Mar; 56(3):93-8. PubMed ID: 12630339
    [Abstract] [Full Text] [Related]

  • 19. Pharmacological mechanism of topical lodoxamide treatment in vernal keratoconjunctivitis: a flow-cytometric study.
    Avunduk AM, Avunduk MC, Dayanir V, Tekelioğlu Y, Dayioğlu YS.
    Ophthalmic Res; 1998 Mar; 30(1):37-43. PubMed ID: 9483586
    [Abstract] [Full Text] [Related]

  • 20. Presence of inflammatory mediators in the tears of contact lens wearers and non-contact lens wearers.
    Tan M, Thakur A, Morris C, Willcox MD.
    Aust N Z J Ophthalmol; 1997 May; 25 Suppl 1():S27-9. PubMed ID: 9267618
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.